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A B S T R A C T
Profiling blood-brain barrier permeability of bioactive molecule is an important issue in early drug development,
being a part of the optimization process of a compound's physicochemical properties, and hence pharmacoki-
netic profile. The study aimed to develop and optimize a new in vitro method for assessment of the compound's
brain penetration. The tool is proposed as an alternative to the PAMPA-BBB (Parallel Artificial Membrane
Permeability Assay for Blood-Brain Barrier) and based on a capillary electrochromatography (CEC) technique. It
utilizes liposomes as structural substitutes of biological membranes, which are used as a capillary inner wall
coating material. Following optimization of analysis conditions, migration times for a set of 25 reference drugs
(mainly non-ionized in pH 7.4) were examined in a liposome coated capillary. On that basis, the retention factor
(log k) was determined for each reference drug. Obtained log k values and experimentally received reference
permeability parameters: log BB (in vivo data) and log Pe (PAMPA-BBB data) were compared with one another.
Correlation coefficients were calculated, giving comparable results for CEC log k/log BB and analogical PAMPA-
BBB log Pe/log BB analyses. Approximate ranges of log k for the central nervous system (CNS) permeable (CNS
(+)) and non-permeable (CNS(−)) drugs were established.
1. Introduction
The drug development process requires both the evaluation of the
pharmacological activity of a newly synthesized molecule and the op-
timization of its pharmacokinetic profile, defined mostly by physico-
chemical properties. Optimal physicochemical properties determine a
compound's permeability through biological membranes, affecting all
ADMET processes (absorption, distribution, metabolism, excretion, and
toxicity). Interaction between a bioactive molecule and the biological
membrane is essential in terms of both, its absorption from the gas-
trointestinal tract and its penetration through the other barriers in the
body, including the particularly important blood-brain barrier (BBB).
For potential central nervous system (CNS) drugs, profiling their BBB
permeability is crucial for the further development of these molecules.
A drug intended to interact with its target (receptor, enzyme or other)
located in CNS must cross the BBB to induce the desired activity. A
compound that lacks optimal physicochemical properties determining
brain penetration is usually disqualified, even despite the strong in vitro
activity toward its biological target. Information about BBB perme-
ability at the early stage of the new molecule development process al-
lows modification of the potential drug structure for its better CNS
exposure. Brain penetration is important not only for drugs acting
within the CNS; it is also essential for peripherally active compounds
due to their possible adverse brain-related effects.
BBB is the continuous layer formed by the brain endothelial cells of
brain capillaries. Transport through the endothelium is highly restricted
because of the presence of complex tight junctions between the cells of
the capillary wall, but also due to the active efflux transporters, mainly
P-glycoprotein (P-gp, MDR1) [1,2]. The main function of the im-
permeability of BBB for many compounds is to protect the brain from
the potentially toxic substances, and also to maintain a constant in-
ternal environment optimal for neuronal function. Thanks to the BBB,
the composition of the extracellular fluid is quite independent of the
composition of the circulating blood [3]. Penetration of the compounds
through the BBB is carried out exclusively by transcellular passive
diffusion or transcellular active/facilitated transport.
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To date, many diverse techniques have been utilized to quantify and
assess the compounds' BBB permeability [4–18]. In general, these are in
vivo, in vitro and in silico methods. In vivo techniques, usually performed
to obtain the log BB (logarithm of brain and blood drug concentration
ratio measured in a steady-state) or log PS (logarithm of the perme-
ability-surface area coefficient) permeability parameters, provide re-
sults based on the real physiological conditions. However, in vivo
measurements are complex, expensive, time-consuming, require ani-
mals and surgical expertise as well as a large amount of highly pure test
compounds. To achieve a high throughput requirement and simulta-
neously to reduce the use of animal models, in vitro and in silicomethods
have been proposed extensively in the recent few decades. In silico
techniques, often based on the quantitative structure-activity relation-
ship and software calculations have become popular for BBB perme-
ability prediction due to their many advantages. These are low cost,
short time of analysis, environment-friendly character and high
throughput; yet still some disadvantages limit the use of the in silico
models in the drug discovery pipeline. The main point is that these
methods involve a large number of molecular descriptors and compli-
cated calculations, still being unable to take into account all the phy-
siological processes occurring in vivo. As a result, experimental data and
in vitro models are still more desired. Often, experimentally obtained in
vitro permeability values are combined with calculated molecular de-
scriptors related to CNS permeability, to achieve better prediction of
drug-membrane transport. In vitro strategies utilize cell-based and non-
cell-based assays. There are several in vitro cell-based methods for the
assessment of both passive diffusion and active transport of compounds
through the BBB. The best of these are those based on primary cultures
of brain capillary endothelial cells, but surrogate BBB models based on
non-cerebral cell lines are also often utilized. Surrogate BBB models
employ epithelial-like cells, such as Madin–Darby Canine Kidney cells
transfected with the human MDR1 gene (MDCK-MDR1 permeability
assay) and the human colorectal adenocarcinoma cell line (Caco-2
permeability assay) [19,20]. However, methods predicting drug BBB
passive and facilitated permeability, investigating possible influx and/
or efflux ratios are costly and time-consuming and are not necessary for
simple passive diffusion studies in the early phase of drug research for
screening compounds. Besides, most CNS drugs, predominantly char-
acterized as small molecules, are transported into the brain mainly
through the passive diffusion [1,3,4,21]. Therefore, in vitro non-cell-
based passive diffusion permeability assays are routinely performed at
the early CNS drug development stage. Among these methods, separa-
tion techniques, as well as the Parallel Artificial Membrane Perme-
ability Assay for Blood-Brain Barrier (PAMPA-BBB), are utilized for BBB
permeability assessment. Separation methods include chromatographic
and electrophoretic strategies, both of which meet low cost, high
throughput, and high reproducibility criteria. In recent years many
research groups have proposed their concepts of modeling drug-mem-
brane transport based on chromatographic principles. Simple reversed-
phase thin layer chromatography (RP-TLC) based model as well as the
methods focused on the reversed-phase high-performance liquid chro-
matography (RP-HPLC) have been developed to obtain experimental
retention parameters [5]. Often, experimental results have been com-
bined with computed molecular descriptors [5,10,11]. To improve the
model of a biological membrane, standard HPLC stationary phases have
been replaced with immobilized artificial membranes (IAM) and uti-
lized for brain permeability studies [12,13]. Also, microemulsion liquid
chromatography (MELC) [14–16], as well as micellar liquid chroma-
tography (MLC) [5,15] and a variant of MLC named biopartitioning
micellar chromatography (BMC) [17] have been proposed, using mi-
celles buffer solutions and microemulsions as mobile phases of a
chromatographic system to more closely mimic the analytes – mem-
branes interactions. G. Russo et al. [18] combined compounds’ exposed
polarity measured experimentally by supercritical fluid chromato-
graphy (SFC) with in silico calculated water-accessible surface area
values and other descriptors to model the uptake of drugs through the
BBB. Despite many advantages of LC-based methods, including high
throughput and excellent repeatability of results, some limitations have
also been reported. These are high consumption of organic solvents
affecting the cost of analyses and often the requirement of the addition
of in silico descriptors to the experimentally obtained permeability
parameters (X. Subirats et al. work [14] is an exception here). In the
case of IAM-based methods, utilized artificial membranes possess the
monolayer structure. As a result, the test compounds only bind to them
and do not pass through the membranes, unlike physiological condi-
tions. In the last years the in vitro electromigration models, based on the
capillary electrophoresis (CE), have been gaining importance in terms
of the application for BBB permeability studies. CE is an analytical
technique based on the separation principles; the analytes are separated
under the influence of the applied voltage, according to their charge,
mass, and structure. Separation of tested compounds in the capillary is
an effect of two phenomena: electrophoretic migration (migration of
charged particles in the electric field toward the oppositely charged
electrode) and electroosmotic flow (EOF) [22]. The EOF is created in
the capillary by the cations migrating toward the cathode, dragging the
solvent (with all ions and neutral particles) along. The cations form a
so-called double electrical layer, as a result of their interaction with
negatively charged silanol groups of the inner wall of a typical silica-
fused capillary. Electrophoretic strategies preserve all LC advantages.
Also, they are characterized by simplicity, high separation efficiency,
economical use of solvents and environment-friendly nature [6]. To
date, CE based microemulsion electrokinetic chromatography (MEEKC)
[7], biopartitioning micellar electrokinetic chromatography (BMEKC)
[9] and liposomal electrokinetic chromatography (LEKC) [8] have been
applied for assessment of compounds brain penetration.
Despite many proposed separation techniques, currently, the
PAMPA-BBB tool is widely used as a high throughput in vitro BBB
permeability testing method, including by our research team [23–25].
The assay was developed by L. Di et al. (2003 [4]), as a modification of
the method for studying biological membranes permeability, dis-
covered and described by M. Kansy et al. (1998 [26]). However, next to
its many advantages, also in this technique some limitations do exist,
primarily because of the non-bilayer lipid structure of the assay's arti-
ficial membrane and dodecane diluent. Besides, the test is quite ex-
pensive for a small academic research team. Therefore, there is a need
for an alternative, rapid and relatively cheap in vitro model, mimicking
human BBB, for assessment of permeability of new compounds with
potential therapeutic use.
The presented study aimed to develop and optimize an in vitro
method for studying BBB permeability of compounds, based on the CE
technique, taking advantage of liposomes as structural analogs of the
natural biological membranes. The developed method might be an al-
ternative to the currently used PAMPA-BBB assay, as a tool for
screening compounds at the early drug discovery stage.
The developed method uses a capillary electrochromatography
technique (CEC) which is a variant of CE. CEC employs a packed or
wall-coated capillary (open-tubular CEC). In an open-tubular CEC, a
chromatographic phase is created in the capillary by covering its inner
surface. Different phospholipids can be used as a capillary coating
material, usually forming a semi-permanent layer, non-covalently at-
tached to the silica wall. In the presented method, the capillary is
covered internally with a phospholipid layer, composed of large uni-
lamellar liposomes (large unilamellar vesicles, LUVs). The coating mi-
mics BBB, as liposomes are structurally similar to the biological cell
membrane. Once the capillary is well coated, the double electrical layer
is still formed, but it is less effective when compared to an uncoated one
because liposomes cover negatively charged silanol groups of the ca-
pillary wall. As a result, a suppressed EOF is observed (Fig. 1). Also, in a
liposome coated capillary, after appropriate modifications of the ana-
lysis conditions, separation of the tested compounds is influenced by
their interaction with the liposomal layer, due to their physicochemical
properties determining permeation (e.g., polar surface area and log P).
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Simultaneously, separation is still dependent on compound charge or
mass parameters which alone impact migration times in the uncoated
capillary. Therefore, the CEC system is defined as a combination of
compound electrophoretic migration and simultaneously its retention
due to the presence of a liposomal coating. For neutral agents or those
predominantly uncharged in the analysis conditions (also for zwitter-
ions with a summary charge equal to 0), their charge related electro-
phoretic migration is minimized and separation is mainly dependent on
the interaction with liposomes.
We assumed that neutral compounds with high BBB permeability
should interact with the liposome layer mimicking the BBB (by entering
the liposomes) and migrate toward the cathode with lower velocity. In
contrast, molecules with low CNS penetration should quickly pass
through the capillary due to the weak interaction with the liposomal
coating (Fig. 1).
In the PAMPA-BBB assay, an extract from a porcine brain containing
specific phospholipids is used to create an artificial membrane that
mimics BBB [4]. In the developed method, phospholipids are utilized to
prepare the liposomal layer of the inner capillary wall. However, unlike
the PAMPA-BBB assay, phospholipids are dissolved in aqueous buffer
solution, where they tend to self-assemble (due to their amphiphilic
properties) into bilayer lamellar structures, spontaneously forming li-
posomes [27,28]. Thus, the created liposomal coating possesses a bi-
layer structure, being closely related to the phospholipid bilayer core of
the cellular membrane. Liposomes are of great interest to investigate
the interactions of compounds with natural phospholipid bilayers
[29,30]. Studies utilizing liposomes in CE were initiated by Zhang et al.,
in 1995 [31]. Subsequently, many original papers have been published
on the application of vesicles in the electrophoretic analysis. Liposomes
have been used as a pseudo-stationary phase in the LEKC technique
[8,32–34] or as a coating material of the inner wall of the capillary
(CEC technique) [33,35–37]. The first successful liposome capillary
coating was carried out by Yang et al., in 1998 [38]. Since that time,
many diverse vesicle compositions and separating conditions have been
studied in the field of the CEC technique [39–42]. So far, however, the
LEKC technique is the only one liposomal chromatographic tool based
on CE to be used for the prediction of gastrointestinal absorption of
compounds [34], and also for testing skin permeability [43] and pe-
netration across the BBB [8]. To the best of our knowledge, to date,
there is no validated and optimized CEC method utilizing liposomes as
the capillary inner wall coating material, which has been applied for the
prediction of BBB penetration of bioactive molecules. Therefore, the
development of such a model seems to be innovative, valuable and
significant for the studies into drug discovery.
The presented CEC method, used for studying the interactions of
compounds with biological membranes retains many CE advantages.
These are the short time of analysis and the precision of the obtained
experimental results, as well as the small amounts of tested compounds
required for successful analysis. Also, substances of low purity can be
used as the impurities are separated from the main product. The au-
tomated instruments make CEC an easy to perform technique; fused
silica capillaries are durable, easy to clean and may be utilized re-
peatedly for different analyses. The amount of phospholipids needed to
create liposomes and perform the study is small (when compared to
methods, where the vesicles are used as a pseudo-stationary phase, like
LEKC and other EKC models), which significantly reduces the cost of
analysis. Besides, the structure and composition of liposomes can be
easily modified, which is useful, considering the method optimization.
Simultaneously, the proposed CEC method retains most of the good
features of the LC-based strategies; it is even considered to be a hybrid
between CE and HPLC techniques. However, as an electrophoretic tool
it is characterized also by simplicity, high separation efficiency, eco-
nomical use of solvents and environment-friendly nature – goals hard to
achieve in case of many LC-based methods. Moreover, unlike HPLC and
IAM-HPLC chromatographic stationary phases, the CEC liposomal layer
mimicking BBB preserves the bilayer structure, characteristic for nat-
ural biological membranes.
The work plan for the development of the BBB permeability mod-
eling method included optimization of the separation conditions, pre-
paration of the appropriate calibration curves and finally method va-
lidation. In the first stage of analysis, described in this paper, after
coating the capillary with a liposomal layer, separation parameters
were optimized. Then, the migration times for the set of 25 selected
reference drugs were examined. On this basis, a logarithm of the re-
tention factor (log k) and the electrophoretic mobility were determined
for each reference drug. Log k values were compared with experimen-
tally obtained reference BBB permeability parameters, such as log BB
(logarithm of brain and blood drug concentration ratio measured in a
steady-state) or log Pe (logarithm of the effective permeability).
Correlation coefficients were calculated on the basis of the prepared
calibration curves. For comparison purposes, linear regression analysis
of log Pe and log BB parameters was also done.
Fig. 1. Scheme of electrophoretic migration (A) and electroosmotic flow EOF (B) in CE and CEC (in the developed method). In CEC variant suppressed EOF is
observed. The blue arrows indicate the direction of the ions and solvent migration in the capillary. The black arrows show the interaction of compounds with a
liposomal layer. CNS(+); CNS(+/−); CNS(−) are compounds with good, uncertain and poor brain permeability, respectively; for simplicity only neutral in pH 7.4.
(For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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2. Materials and instruments
2.1. Chemicals
References (purity > 99.5%) were purchased as follows: acet-
aminophen, aminophenazone carbamazepine, cetirizine dihy-
drochloride, hexobarbital sodium, levodopa, norfloxacin, omeprazole,
theobromine, theophylline (Sigma Aldrich, Steinheim, Germany); caf-
feine, phenytoin (Alfa Aesar, Kandel, Germany); antipyrine (Fluka,
Seelze, Germany); barbital (Polfa Tarchomin, Warszawa, Poland); hy-
drocortisone (Fagron, Kraków, Poland); and progesterone (Caesar &
Loretz, Hilden, Germany). The following drugs were extracted with
chloroform from tablets: alprazolam (Zomiren SR; KRKA, Nove Mesto,
Slovenia); diazepam (Relanium; GlaxoSmithKline Pharmaceuticals,
Poznań, Poland); digoxin (Digoxin Teva; Teva Pharmaceuticals,
Warszawa, Poland); fexofenadine (Fexofast; Galena, Wrocław, Poland);
fluconazole (Fluconazole; Polfarmex, Kutno, Poland); lamotrigine
(Lamilept; Teva Pharmaceuticals, Warszawa, Poland); midazolam
(Dormicum; Roche, Warszawa, Poland); oxazepam (Oxazepam; Espefa,
Kraków, Poland); and zolpidem (Zolsana; KRKA, Nove Mesto,
Slovenia); the solvent (chloroform) was then evaporated to dryness.
Methanol (hypergrade for LC-MS), chloroform (HPLC purity), so-
dium hydroxide (NaOH, 1.0 M, CE purity), HEPES buffer (40 mM, pH
adjusted to 7.4 by addition of 1.0 M NaOH), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), 1,2-diacyl-sn-glycero-3-phospho-L-
serine (PS), and porcine Brain Polar Lipid Extract (Avanti, Alabaster,
AL, USA) were obtained from Sigma Aldrich (Steinheim, Germany).
Hydrochloric acid (HCl, 36%) was purchased from Stanlab (Lublin,
Poland). Purified water was derived from the deionization unit
(Hydrolab, Straszyn, Poland). HEPES buffer and HCl were filtered
(0.45 μm pore size filter) before use.
2.2. Materials
Polycarbonate filter units of 0.1 μm pore size and the syringe filter
units with a pore size of 0.45 μm were purchased from Sigma Aldrich
(Steinheim, Germany). Uncoated fused-silica capillary (Beckman
Instruments, Fullerton, CA, USA) 59.1 cm × 50 μm of internal diameter
and 375 μm of external diameter, with an effective length of 49 cm was
used throughout the study. Alternatively, we used a capillary of 20 μm
in internal diameter (other parameters unchanged) obtained from
Labstore (Warsaw, Poland).
2.3. Instruments
All CEC analyses were performed on a P/ACE MDQ instrument with
a DAD detector (Beckman Instruments, Fullerton, CA, USA). The UV
detection of the analytes was carried out at a wavelength of 220 nm. We
used 32 Karat Software version 8.0 to record and analyze obtained
electropherograms. Liposome extrusion was performed using
LiposoFast Liposome Factory (Avestin Europe, Mannheim, Germany).
3. Methods – optimization of the new CEC method
3.1. Separation buffer
All experiments were performed using 40 mM HEPES buffer (pH
7.4) as the background electrolyte solution. According to the earlier
studies [35,37] on CEC with phospholipid liposome coatings, HEPES
buffer has been found to be the best one to achieve a good liposome
layer in a fused-silica capillary. In pH 7.4, protonated piperazine amino
groups of HEPES are able to act as linkers between a negatively charged
fused-silica capillary wall and anionic liposomes, resulting in a stable
capillary coating.
3.2. Liposome composition and preparation
The anionic liposomes used in the main study were composed of
POPC and bovine brain PS in the molar ratio 80:20 mol% (POPC/PS
liposomes). According to the literature [35], such composed vesicles
cover the inner wall of the capillary in a stable way, thus enabling ef-
fective separation of tested compounds. It is also known, that a capillary
coating composed of LUVs gives better repeatability of the EOF in
comparison with the layer prepared of multilamellar vesicles (MLVs),
due to the homogeneity of LUVs, which is hard to achieve in case of
MLVs [44]. Therefore, in the developed method we utilized LUVs that
were produced by extrusion of MLVs solution.
To prepare liposomes, appropriate amounts of phospholipids were
dissolved in an organic solvent (chloroform, methanol) to form lipid
stock solutions. Resultant stock solutions were mixed in order to give
the desired composition with an appropriate molar ratio. The mixture
was evaporated to dryness under a stream of argon and left for 24 h
under the low pressure to evacuate traces of solvent. Lipid residues
were next hydrated in separation buffer at 60 °C (lipid concentration of
4 mM) and maintained at this temperature for 1 h with vigorous vor-
texing. Obtained MLVs were processed into LUVs by 19 times extrusion
through 0.1 μm pore size polycarbonate filters. The liposome solutions
were stored in a refrigerator and used within 6 days.
Alternatively, we used anionic liposomes prepared from porcine
Polar Brain Lipid (PBL) Extract (also utilized in the PAMPA-BBB assay
[4]), according to the procedure described above. PBL Extract utilized
in this study is composed of various phospholipids, including phos-
phatidylcholine (12.6%), phosphatidylethanolamine (33.1%), phos-
phatidylinositol (4.1%), PS (18.5%) and phosphatidic acid (0.8%). It
also contains 30.9% of the unknown, mainly lipid components (cere-
brosides, sulfatides), so the concentration of the prepared liposomal
solution was defined as approximately 4 mM. The obtained liposomal
solution was diluted to approximately 3 mM and used as a capillary
coating material.
Since PBL Extract contains over 23% of negatively charged phos-
pholipids (PS, phosphatidylinositol and phosphatidic acid), both PBL
and POPC/PS liposomes were negatively charged.
3.3. Sample preparation
Each tested compound – in the amount of approximately 1.5 mg –
was dissolved in 1 mL volume of methanol to give a stock solution.
Prepared stock solutions were mixed with separating HEPES buffer
(40 mM) in a 1:9 ratio and filtered through the 0.45 μm pore size filters
to give final samples, ready for the injection into the capillary.
Methanol, used as a solvent for the compounds, was also the EOF
marker.
3.4. Coating procedure
The inner capillary wall was covered with a LUV layer, according to
the known procedure [35], with only small modifications.
Liposomes may form two types of coatings on the silica surface of a
capillary wall: a supported phospholipid bilayer (SLB) or a supported
vesicular layer (SVL). The type of formation and the effectiveness of the
capillary coating process has been studied, using atomic force micro-
scopy [45–47], or the dissipative quartz crystal microbalance (QCM)
technique. Viitala et al. [48] used the QCM technique to analyze the
formation of a capillary layer, created by liposomes composed of the
same phospholipid components (POPC/PS) as utilized in this study. The
obtained coating was characterized as a viscoelastic and stable SVL
type. The SVL layer is more suitable for the CEC technique, because it
increases the probability of interaction between analytes and lipo-
somes, due to its larger surface area in comparison to the SLB layer.
The coating process was conducted as follows: 10 min of rinsing the
capillary with 0.5 M HCl under the pressure of 93.8 kPa; next, 15 min of
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rinsing with water; and finally, 10 min of rinsing with the 3 mM lipo-
some solution, both also under the pressure of 93.8 kPa. Then the ca-
pillary was left to stand filled with the liposome solution for another
15 min.
The effectiveness of the coating procedure was verified by mea-
suring the EOF changes in the coated capillary in comparison to the
uncoated one. The electroosmotic mobility μeof was determined using
methanol as a neutral marker, as it displays almost no interaction with
the capillary wall [49]. In a covered capillary, the EOF was suppressed,
and the methanol μeof value was lower (see results section). The efficacy
of the capillary coating was also confirmed by the separation of the
mixture of tested drugs (Fig. 2).
In a liposome coated capillary, separation of references was influ-
enced by their interaction with the liposomal layer. Compound mi-
gration times were prolonged for all references (due to suppressed
EOF), yet calculated log k parameters varied according to drug affinity
to liposomes. For molecules with weak liposome interaction, almost no
differences in log k values were observed, between experiments con-
ducted in coated and uncoated capillaries.
3.5. Separating conditions
Electrophoretic runs were conducted at the normal polarity mode,
under the 20 kV voltage, resulting in a current of about 10 μA. Also,
13 kV and 10 kV voltages were tested to achieve the best compound
separation. A lower voltage resulted in a small separation improvement,
but an unfavorable prolonged time of analysis was observed (Fig. 3).
The temperature of the capillary chamber was set to 25 °C, ac-
cording to the previously reported procedure [35], as it provides sa-
tisfactory repeatability of the electroosmotic flow both in the uncoated
and the in the coated capillary. Prior to each analysis, the capillary was
rinsed with 40 mM HEPES buffer pH 7.4 for 2 min (93.8 kPa), to
eliminate any unbound liposomes and other contaminations. The
sample was injected into the capillary at a pressure of 4.8 kPa with a
duration time of 6 s (50 μm capillary) or at a pressure of 13.8 kPa with
7 s of duration time (20 μm capillary). After sample injection, the ends
of the capillary were cleaned by immersion in water for 0.05 min, thus
avoiding contamination of other solutions. 40 mM HEPES buffer pH 7.4
was used as a separation solute. The buffer was changed in vials every
six runs to ensure its quality. The time of analysis was approximately
5–7 min for 20 kV voltage, and up to 11–14 min for 10 kV voltage. Each
experiment was performed in triplicate. To remove the capillary lipo-
somal coating, the cleaning procedure was followed by 10 min of water
rinsing, then 40 min of flushing with a mixture of chloroform and
methanol in a 2:1 ratio (v/v) and finally 5 min of air drying, all steps
with 93.8 kPa pressure.
4. Methods – PAMPA-BBB assay
The penetration of the reference compounds across BBB was esti-
mated using the PAMPA-BBB assay in order to obtain the experimental
log Pe parameters. In this study, PAMPA-BBB was used as a non-cell-
based in vitro assay [23,25] carried out in a coated 96-well membrane
filter. The filter membrane of the donor plate was coated with PBL
(Avanti, USA) in dodecane (4 μL of 20 mg/mL PBL in dodecane) and the
acceptor well was filled with 300 μL of phosphate buffer saline, (PBS pH
7.4; VA). The tested compounds were first dissolved in dimethylsulf-
oxide (DMSO) and then diluted with PBS pH 7.4 to reach the final
concentrations of 50–500 μM in the donor well. The final concentration
of DMSO did not exceed 0.5% (v/v) in the donor solution. A total of
300 μL of the donor solution (VD) was added to the donor wells and the
donor filter plate was carefully put on the acceptor plate so that the
coated membrane was “in touch” with both donor solution and acceptor
buffer. In principle, a test compound diffused from the donor well
through the PBL membrane (Area = 0.28 cm2) to the acceptor well.
The concentrations of the tested compound in both donor and the ac-
ceptor wells were assessed after 3, 4, 5 and 6 h of incubation respec-
tively in quadruplicate using a Synergy HT UV plate reader (Biotek,
USA) at the maximum absorption wavelength of each compound
(n = 3) or by HPLC/MS (n = 2), where a low signal was observed by
UV-VIS spectrophotometry (i.e. barbital, cetirizine, digoxin, hex-
obarbital, phenytoin). In addition, a solution of theoretical compound
concentration, simulating the equilibrium state established if the
membrane were ideally permeable, was prepared and assessed as well.
Concentrations of the compounds in the donor and acceptor wells and
equilibrium concentrations were calculated from the standard curve










where VA is the volume of the acceptor compartment, VD is the donor
well volume, Area is the accessible filter area andTime is the incubation
time.
4.1. UHPLC-MS specification
UHPLC-MS analysis of selected donor and acceptor solutions was
Fig. 2. Separation of hydrocortisone and pro-
gesterone mixture under applied voltage of
20 kV, in the uncoated capillary (black marked)
and in the POPC/PS liposome coated capillary
(red marked), both 50 μm of internal diameter.
In the presence of the liposomal coating, se-
paration of both steroids occurs. Due to the re-
tention, progesterone migrates toward cathode
with lower velocity. Hydrocortisone interaction
with the phospholipid layer is weak. Black peaks
in order: methanol, unseparated hydrocortisone
and progesterone peak. Red peaks in order:
methanol, hydrocortisone, progesterone. (For
interpretation of the references to color in this
figure legend, the reader is referred to the Web
version of this article.)
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carried out using a Dionex UltiMate 3000 RS UHPLC analytical system
coupled with a Q Exactive Plus hybrid quadrupole-orbitrap mass
spectrometer (MS). This equipment was used to determine high-re-
solution mass spectra (HRMS) and unknown concentrations of five
compounds resulting from the PAMPA-BBB assay (barbital, cetirizine,
digoxin, hexobarbital, phenytoin). The chromatographic system in-
cluded the following modules: HPG-3400RS binary pump, vacuum de-
gasser, TCC-3000RS heated column compartment, and WTS-3000RS
autosampler equipped with a 25 μL loop and DAD-3000 detector. A
Phenomenex Kinetex C18 EVO column (3.0 × 150 mm/2.6 μm; 100 Å)
was chosen as the stationary phase. The temperature in the column
thermostat was set to 27 °C. The chromatographic analyses were per-
formed by the reverse phase gradient elution method with mobile phase
A: 0.1% (v/v) formic acid in ultrapure water of ASTM I type (resistance
18.2 MΩ × cm at 25 °C) prepared with a Barnstead Smart2Pure 3 UV/
UF apparatus (Thermo Fisher Scientific, Bremen, Germany) and mobile
phase B: 0.1% (v/v) formic acid in LC-MS grade acetonitrile. For the
elution, a simple linear gradient program mixing ultrapure water (MPA)
and acetonitrile (MPB), both acidified with 0.1% (v/v) of formic acid,
was developed: 0–1.0 min 10% MPB, 1.0–4.0 min 10–100% MPB,
4.0–5.0 min 100% MPB, 5.0–5.0 min 100-10% MPB, 5.0–7.5 10% MPB.
The flow-rate of the mobile phase was set to 0.4 mL/min and the in-
jection volume to 5 μL. In MS, heated electro-spray ionization (HESI)
was utilized (setting: sheath gas flow rate 55, aux gas flow rate 15,
sweep gas flow rate 3, spray voltage 3.5 kV, capillary temperature
220 °C, aux gas temperature 220 °C, S-lens RF level 50). Ions were
monitored in the range of 150–1000 m/z in positive mode with the
resolution set to 140,000. The chromatograms and mass spectra were
processed on Chromeleon 6.80 and Xcalibur 3.0.63 software, respec-
tively. The substances were identified according to their high-resolution
mass to charge ratio. In order to determine the unknown concentrations
of the studied compounds in the donor and acceptor solutions, a cali-
bration measurement spanning the range of 5–100 μg/mL was carried
out. The linearity of calibration across its 5 points range was confirmed
with R2 > 0.9910 for all compounds.
5. Results and calculations
In the first stage of method development, we selected 25 reference
drugs, with varying BBB permeability, diverse structure and lipophili-
city, neutral or predominantly unionized (also few zwitterions with a
summary charge equal to 0) in analysis conditions (pH 7.4). For these
compounds, the influence of the electric field on their migration times
was minimized and separation was mainly dependent on the interaction
with liposomes. During method optimization, separation conditions
were established in order to test all 25 references, preserving a rea-
sonable time for their migration in the capillary. At first, we used a
capillary with 50 μm of internal diameter and POPC/PS liposomes
(80:20 mol%). In the preliminary research, the separation time was best
for 20 kV voltage analysis, however, it was still acceptable for an ex-
periment conducted under the voltage of 10 kV. Therefore, we decided
to perform separation of all references under 20 kV and 10 kV voltage
(other parameters of analysis were unchanged) and compare obtained
correlation coefficients in both conditions. After coating the capillary
with POPC/PS liposomes, 25 compounds were analyzed and their log k
parameters were calculated on the basis of their migration times, ac-
cording to the Equation (2),
= t t
t
log k log R EOF
EOF (2)
where tR, tEOF are the migration times (min) of the solute and the EOF
marker (methanol), respectively.
The retention factor (k) is defined as the ratio of the total number of
moles of analyte in the stationary and aqueous phase [52].
Equation (2) is a simplification of Equation (3) used by Terabe et al.







EOF t tR MC (3)
where tMC is the migration time of micelles i.e. pseudo-stationary phase.
In the developed method liposomes, a stationary phase analogical to
micelles, are attached to the capillary wall, so they never exit the ca-
pillary and their migration time becomes infinite t( MC ).
Determined log k parameters (Table 1) were used for quantitative
and qualitative purposes. In terms of qualitative permeability assess-
ment, references can be classified as easy brain penetrators CNS(+) and
poor brain penetrators CNS(−), according to their log k values. Sub-
sequently, approximate ranges of log k for CNS permeable and non-
permeable drugs were established on the basis of their literature CNS
(+)/CNS(−) classification [4,53–64]. References with log k values
lower than −1.84 or higher than −1.61 (analysis under 20 kV voltage,
with POPC/PS coating) were predominantly (75%) correctly assessed as
CNS(−) or CNS(+) agents, respectively (Table 2). In the case of the
PAMPA-BBB analogical log Pe ranges, there are 77% of the correct as-
sessments of the CNS(+) and CNS(−) compounds; both CEC and
PAMPA-BBB analyses are based on the experimentally obtained log k
and log Pe values.
From the quantitative point of view, the model needs to be eval-
uated for its predictive ability. For this purpose, log k parameters were
compared with experimental literature log BB data [65–69] (in vivo
Fig. 3. Separation of a mixture of 5 reference drugs
(peaks in order: methanol, norfloxacin, hydro-
cortisone, theophylline, hexobarbital, phenytoin),
under applied voltage of 20 kV (marked in black),
13 kV (marked in blue) and 10 kV (marked in
green). A 50 μm of internal diameter capillary,
POPC/PS liposome coating. (For interpretation of
the references to color in this figure legend, the
reader is referred to the Web version of this article.)
J. Godyń, et al. Talanta 217 (2020) 121023
6
measurements obtained from rats), and with log Pe values obtained
experimentally in the PAMPA-BBB assay. All data are collected in
Table 1.
The Pe value is expressed in [10−6cm × s−1] units and describes
the penetration rate of the compound across the membrane. The log Pe
parameters were calculated, according to Equation (1).
The obtained log k values and permeability parameters were plotted
to give the calibration curves described by linear equations Equation
(4) and Equation (5),
log BB = a log k + b (4)
log Pe = c log k + d (5)
where a, c represent the slopes and b, d are the intercepts of the cali-
bration curves, respectively.
Correlation coefficients were determined for both 20 kV and 10 kV
voltage separations. In the case of log k and log BB correlation (Fig. 4A),
four compounds (caffeine, levodopa, cetirizine, and barbital) were ex-
cluded, as their log BB values were reported to be affected by processes
other than only passive diffusion [4,70–75]. Linear regression for log k
and log Pe parameters (Fig. 4B) was prepared on the basis of data for 22
compounds, with 3 more excluded from the final analysis (barbital,
fexofenadine, and zolpidem) as outliers (see discussion section).
To compare PAMPA-BBB reference experimental results with in vivo
permeability data, correlation analysis was prepared for log Pe and log
BB parameters (Fig. 5). The same 4 drugs were excluded from linear
regression as in case of analogical correlation of CEC retention factors
and log BB (caffeine, levodopa, cetirizine, and barbital). The obtained
R2 coefficient was comparable to those calculated for log k and log BB
parameters (Fig. 4A). Log k values obtained for 20 kV CEC analysis
correlated even better with in vivo data than log Pe values from re-
ference method (R2 = 0.4258 versus R2 = 0.3678, for CEC and
PAMPA-BBB, respectively).
Total electrophoretic mobilities of reference compounds were also
calculated (Fig. 6). The electrophoretic mobility μtot of an analyte is
defined as the sum of the electroosmotic mobility in the capillary μeof
and the electrophoretic mobility of the analyte itself μep (Equation (6)).
+=µ µ µtot ep eof (6)
The total electrophoretic mobility μtot was obtained using Equation
(7),
= × ×µ V
E
[cm V s ]tot
tot 2 1 1
(7)
where Vtotis electrophoretic velocity [cm × s−1] obtained by dividing
the effective capillary length by the migration time of the analyte, and
E is the magnitude of the applied electrical field, calculated by dividing
the applied voltage by total capillary length [V × cm−1].
The electroosmotic mobility μeof (marked by methanol) was calcu-
lated analogically to total electrophoretic mobility, using Equation (7).
The μeof parameter was used for assessment of the effectiveness of the
capillary coating process (Table 3).
We also tested the separation of reference compounds in a capillary
of 20 μm of internal diameter, with a coating composed of POPC/PS
(80:20 mol%) liposomes. The liposomal layer was stable, as suppressed
EOF was observed (Table 3), but no favorable changes in the separation
of tested references were obtained. Unexpectedly, log k parameters of
tested drugs were lower, indicating weaker interaction of those
Table 1
Log k and log Pe values determined by experimental methods (CEC and PAMPA-BBB, respectively). Log BB values are experimental data retrieved from the lit-
erature[65−69].
reference CEC POPC/PSa CEC PBLb log BBd PAMPA-BBB
log kc± SD log kc± SD log kc± SD log Pe
at 20 kV at 10 kV at 20 kV
acetaminophen −1.603 ± 0.001 −1.573 ± 0.005 −1.618 ± 0.010 −0.31 −6.081
alprazolam −1.601 ± 0.008 −1.557 ± 0.002 −1.639 ± 0.020 0.044 −4.968
aminophenazone −1.715 ± 0.069 −1.810 ± 0.013 −1.815 ± 0.003 0 −4.822
antipyrine −1.635 ± 0.022 −1.597 ± 0.001 −1.700 ± 0.009 −0.097 −5.889
barbital −0.656 ± 0.016 −0.639 ± 0.031 −0.696 ± 0.001 −0.25 −6.921
caffeine −1.845 ± 0.026 −1.705 ± 0.008 −1.735 ± 0.010 −0.055 −5.405
carbamazepine −1.495 ± 0.002 −1.525 ± 0.001 −1.535 ± 0.003 −0.14 −4.894
cetirizine −1.020 ± 0.001 −1.086 ± 0.006 −1.041 ± 0.004 −1.3 −5.524
diazepam −1.476 ± 0.087 −1.586 ± 0.014 −1.524 ± 0.008 0.52 −4.710
digoxin −2.209 ± 0.070 −2.319 ± 0.063 −2.265 ± 0.035 −1.23 −7.097
fexofenadine −2.208 ± 0.104 −2.089 ± 0.093 nde −0.98 −4.987
fluconazole −1.701 ± 0.020 −1.648 ± 0.005 −1.645 ± 0.028 −0.22 −5.241
hexobarbital −1.058 ± 0.001 −1.055 ± 0.003 −1.075 ± 0.004 0.1 −4.655
hydrocortisone −1.610 ± 0.011 −1.702 ± 0.029 −1.543 ± 0.029 −0.9 −5.400
lamotrigine −1.527 ± 0.010 −1.548 ± 0.017 −1.481 ± 0.004 0.48 −5.106
levodopa −1.458 ± 0.009 −1.442 ± 0.011 −1.474 ± 0.008 −0.77 −5.325
midazolam −1.550 ± 0.013 −1.451 ± 0.018 −1.600 ± 0.008 0.36 −4.695
norfloxacin −2.193 ± 0.032 −2.032 ± 0.051 −2.350 ± 0.031 −1 −6.348
omeprazole −1.387 ± 0.001 −1.395 ± 0.006 −1.421 ± 0.004 −0.82 −5.102
oxazepam −1.080 ± 0.057 −1.390 ± 0.040 −1.526 ± 0.005 0.61 −4.659
phenytoin −0.924 ± 0.005 −0.906 ± 0.011 −0.965 ± 0.015 −0.04 −5.043
progesterone −1.283 ± 0.128 −1.406 ± 0.018 −1.438 ± 0.004 0.2 −5.075
theobromine −1.631 ± 0.001 −1.701 ± 0.002 −1.700 ± 0.012 −0.28 −5.996
theophylline −1.231 ± 0.004 −1.229 ± 0.003 −1.307 ± 0.001 −0.29 −5.719
zolpidem −2.169 ± 0.024 −2.122 ± 0.037 nd −0.54 −4.695
a Capillary with 50 μm internal diameter, coated with POPC/PS liposomes (80:20 mol%).
b Capillary with 50 μm internal diameter, coated with porcine PBL Extract liposomes.
c Means of three experiments.
d In vivo measurements from rats.
e Not defined due to overlapping peaks of methanol and reference.
J. Godyń, et al. Talanta 217 (2020) 121023
7
compounds with the liposomal coating (Table 4). We compared log k
parameters calculated for 5 reference compounds according to their
migration times in capillaries with 50 μm and 20 μm of internal dia-
meter, under an applied voltage of 20 kV. As the obtained correlation
coefficient was very high (R2 = 0.9962), we did not conduct the ana-
lysis for all 25 references. Less effective separation of tested compounds
was probably caused by the worse quality of the obtained liposomal
layer. The type and effectiveness of this coating require verification by
additional studies (e.g., QCM technique).
In the course of method optimization, liposomes prepared from
porcine PBL Extract were also utilized as a coating material for a ca-
pillary with 50 μm internal diameter. The coating was stable, and the
EOF was suppressed, however not as well as in the case of POPC/PS
vesicles (Table 3). Subsequently, the separation was less effective, as
the interaction between the tested references and the covered capillary
wall was in general slightly weaker in comparison to a POPC/PS lipo-
somal coating (lower log k parameters obtained; comparison between
50 μm capillaries, separation at 20 kV voltage) (Table 1). The correla-
tion coefficients calculated from linear regressions of log k and log BB
as well as log k and log Pe parameters were also less satisfactory than
the analogical ones obtained for POPC/PS coating (R2 = 0.2601,
F = 5.98, p = 0.0257, n = 19: for log k and log BB analysis and
R2 = 0.3447, F = 10.52, p = 0.0041, n = 22: for plotted log k and log
Pe values). The PBL liposomal coating type and quality also need to be
verified by additional studies (QCM or other), as well as the size of the
PBL liposomes and their surface charge (e.g. zeta potential).
6. Discussion
Optimization of the operating conditions was the critical step for the
new CEC method development. Many parameters were tested in order
to obtain a satisfactory compounds' separation, simultaneously preser-
ving a reasonable migration time for the tested references and mi-
micking, as far as possible, physiological conditions during analysis. As
a result, we successfully covered the capillary with the liposomal layer,
which enabled us to separate all 25 reference compounds and calculate
their log k parameters based on their migration times. We tested two
different liposome compositions, preparing LUVs composed of POPC/
PS (80:20 mol%, according to literature data [35]) and vesicles com-
posed of porcine PBL Extract. Both types of liposomes were able to
cover the inner capillary wall, and the effectiveness of the created layer
was confirmed by reduced EOF. However, the liposomes composed of
POPC and PS phospholipids seemed to be more suitable for the devel-
oped method, due to their stronger interaction with the tested com-
pounds in the capillary. Also, the composition of POPC/PS is constant,
in contrast to brain lipid vesicles, which contain approximately 31% of
unknown lipids. During method optimization, we used POPC/PS lipo-
somes as a coating material for capillaries of 50 μm and 20 μm internal
diameter. As the liposomal LUV coating has a thickness of only about
70 nm [38] (SVL type layer), it is expected that the narrower the ca-
pillary is, the better should be the interaction between liposomes and
tested compounds. That was not confirmed by the study results. The log
k parameters of tested drugs were lower in the 20 μm capillary
(Table 4), so the compounds migrated with higher velocity toward the
cathode, although EOF was more suppressed in comparison to the
50 μm capillary (Table 3). This was probably due to the poor quality of
the obtained liposomal layer. Therefore, we decided to conduct the
analysis in a capillary with 50 μm internal diameter, testing if the
change of applied voltage enabled an improvement in the separation
parameters. The voltage of 20 kV was the best to combine the short
migration time of references with their satisfactory separation in the
capillary. However, the time of separation was no longer than 14 min,
even under the application of 10 kV voltage. That is why we decided to
use data received under voltages of 20 kV and 10 kV in the presented
analysis, to compare correlation coefficients obtained in both condi-
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with log BB values obtained in vivo. The correlation between log k and
log BB parameters was acceptable only when 4 references (caffeine,
levodopa, cetirizine, and barbital) were excluded from the analysis, and
better for separation under 20 kV voltage. This is in accordance with
the literature data [76], recommending caution while correlating log
BB values with in vitro obtained passive permeability parameters. Brain
and blood drug concentration ratio measured in vivo in rats in a steady-
state takes into account drug distribution through BBB by both passive
diffusion and facilitated (influx and/or efflux) transport. The log BB
value is also affected by other processes such as drug metabolism or
plasma protein binding. Thus obtained CEC log k values should be
correlated with log BB data only for compounds displaying a mainly
passive BBB penetration route. Similar problems were noticed during
the PAMPA-BBB method development. Reference drugs were mis-clas-
sified as false CNS(+) if they underwent rapid metabolism in systemic
circulation or efflux by the P-gp protein, and as false CNS(−) if they
were transported into the brain by both passive diffusion and carrier-
mediated transport. Among the CEC tested references caffeine and le-
vodopa undergo facilitated brain uptake [4,77] (in the case of levo-
dopa, also opposite Na+ - dependent transport from the brain to the
bloodstream is reported [71]) and their permeability data decrease
correlation significance (Fig. 7). In consequence, we decided to exclude
them from the prepared log k and log BB calibration curve. Another
issue concerns references which are easily permeable across BBB
through passive diffusion but are eliminated from CNS by efflux
Fig. 4. Calibration curves obtained by linear regression for the reference compounds (Fig. 4A). Plotted values: log k and log BB parameters (Fig. 4B); Plotted values:
log k and log Pe parameters. Electrophoretic analysis in POPC/PS (80:20 mol%) coated capillary with 50 μm internal diameter, under applied voltage of 20 kV and
10 kV; drugs defined as BBB non-permeable (CNS(−)) are marked in pink. Drugs with good BBB permeability (CNS(+)) are marked in black. CNS permeability
classification based on literature data4,53−64. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this
article.)
Fig. 5. Comparison of permeability data from PAMPA-BBB method and in vivo
experiments from rats. Plotted values: log Pe and log BB. Drugs defined as BBB
non-permeable (CNS(−)) are marked in pink. Drugs with good BBB perme-
ability (CNS(+)) are marked in black. CNS permeability classification based on
literature data4,53−64. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
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transporters. According to the literature data [72,73], cetirizine un-
dergoes efflux elimination, P-gp and not P-gp mediated. Its log BB
parameter value determined in vivo is low (log BB = −1.3 [69]), in-
dicating a low CNS drug concentration in a steady state. However, ce-
tirizine is reported to be able to passively cross BBB and induce weak
CNS related adverse effects (sedation) [73]. The in silico calculated drug
log BB value, based on Abraham descriptors [67], is much higher (log
BB = 0.1 [54]). The log k parameter, determined in the CEC method
was also relatively high (log k = −1.01; Table 1), indicating the
compound's interaction with the liposomal coating. As a result, the
permeation was overestimated using the CEC method, and the drug was
an outlier in the linear regression analysis (Fig. 7). Among the tested
references, fexofenadine, digoxin, and norfloxacin are also eliminated
from the brain by efflux transporters. Fexofenadine and digoxin un-
dergo P-gp and non-P-gp mediated BBB efflux [72,78], but uptake
transport is also involved in their distribution between blood and brain
[61,79]. As a result, the correlation between fexofenadine and digoxin
log k and log BB values was satisfactory in terms of the presented linear
regression analysis (20 kV). However, for norfloxacin, a substrate for P-
gp and non-P-gp efflux transporters [78], no active uptake mechanism
has been reported. Nevertheless, the drug displayed weak in vitro in-
teraction with the liposomal layer, probably due to its physicochemical
properties (i.e. log P = −1.03), that also determine its poor in vivo
membrane permeability, and it was not excluded from the correlation
of log k and log BB parameters.
Log BB as a composite parameter also depends on factors other than
passive and active transport. These are rapid drug metabolism, low
partitioning to the brain tissue, sink effect of cerebrospinal fluid and
high plasma protein binding. The low log BB value may be a signal of
extensive drug binding to serum albumin or other carrier proteins in
blood plasma [74]; on the other hand, the unbound compound's frac-
tion may still be able to cross BBB and cause the desired pharmacolo-
gical effect. Among the analyzed references, barbital displays low log
BB value (log BB = −0.25), and as the acidic drug, it is reported to be
bound by serum albumin [75]. Despite this fact, barbital is classified as
CNS(+) agent [59], penetrating the brain by passive diffusion. Its de-
termined CEC log k parameter was high (Table 1); when plotted with its
low log BB value, the correlation coefficient was significantly weaker
(R2 = 0.3206, n = 22 and R2 = 0.4258, n = 21; with and without
barbital, respectively, the voltage of 20 kV; Fig. 7). Subsequently,
barbital was excluded from the correlation analysis.
The same references (caffeine, levodopa, cetirizine, barbital) were
excluded from linear regression prepared for PAMPA-BBB log Pe ex-
perimental data and log BB values (Fig. 5). Analogically to CEC method,
Fig. 6. Electropherogram presenting
the separation of mixture of five re-
ference drugs i.e. (1) theobromine
(μtot= 3.71 × 10−8 m2 × V−1 × s−1),
(2) hydrocortisone (μtot = 3.64 ×
10−8 m2 × V−1 × s−1), (3) theo-
phylline (μtot = 3.49 × 10−8 m2 ×
V−1 × s−1), (4) phenytoin (μtot =
3.28 × 10−8 m2 × V−1 × s−1) and
(5) barbital (μtot = 2.99 × 10−8 m2 ×
V−1 × s−1); methanol (the EOF
marker) peak is marked as M.
Experimental conditions: 59.1 cm ca-
pillary (49 cm to detector window)
with 50 μm internal diameter; POPC/
PS liposome coating; temperature:
25 °C; separation buffer: 40 mM HEPES
at pH 7.4; sample: 1:9 diluted methanol
stock solution of compound (1.5 mg/
mL) in separation buffer; applied vol-
tage: +20 kV; direct UV detection at
220 nm.
Table 3
Suppression of the electroosmotic flow in a coated capillary with 50 and 20 μm internal diameter. Relative standard deviation (RSD) [%] indicates the EOF stability.
Applied voltage: 20 kV.
Capillary/coating 50 μm uncoated 50 μm POPC/PSa 50 μm PBLb 20 μm uncoated 20 μm POPC/PSa
μeof x 10−8 [m2 x s−1 x V−1] 4.87 4.11 4.26 5.69 4.87
RSD [%] 7.18 8.40 8.61 0.41 2.75
number of measurements 45 100 70 3 15
a Capillary coated with POPC/PS liposomes (80:20 mol%).
b Capillary coated with porcine PBL Extract liposomes; the PBL liposomal coating quality as well as the size of the PBL liposomes and their surface charge need to
be verified by additional studies.
Table 4
Log k values of selected reference compounds, calculated on the basis of their
migration times in capillary with 50 μm and 20 μm internal diameter, with
POPC/PS liposomal coating, under applied voltage of 20 kV.
Compound log ka± SD for capillary/coating
50 μm POPC/PSb 20 μm POPC/PSb
barbital −0.656 ± 0.016 −0.815 ± 0.010
diazepam −1.476 ± 0.087 −1.768 ± 0.010
phenytoin −0.924 ± 0.005 −1.074 ± 0.004
theophylline −1.231 ± 0.004 −1.484 ± 0.001
theobromine −1.631 ± 0.002 −1.898 ± 0.003
a Mean of three experiments.
b Capillary coated with POPC/PS liposomes (80:20 mol%).
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PAMPA-BBB data seemed not to correlate very well with log BB values
for compounds with other than passive diffusion processes involved in
their permeation (R2 = 0.2472, F = 7.552, p = 0.0115 for all 25
analyzed drugs, and R2 = 0.3678, F = 11.06, p = 0.0036, for 21 re-
ferences).
Finally, we decided to compare log k and log Pe parameters de-
termined by the passive diffusion models: CEC and PAMPA-BBB, re-
spectively. Correlation coefficients were calculated (Fig. 4B); however,
3 compounds were classified as outliers and excluded from the analysis.
Obtained R2 values were comparable to those from corresponding log k
and log BB regressions (Fig. 4A). It is worth emphasizing, that the
PAMPA-BBB method gives information about the penetration rate of
tested compounds, which are classified as CNS(+) or CNS(−) based on
their Pe values. In turn, using the CEC method we can assess molecules'
affinity to the phospholipid bilayer rather than their permeability rate.
Low lipid-soluble drugs penetrate slowly through the membrane; still,
they display interference with the lipid bilayer. Usually, they are also
able to penetrate CNS and induce pharmacological effects. Such com-
pounds may be characterized by low Pe values that do not correlate well
with corresponding log k parameters. That was the reason why barbital
was an outlier in the presented log k and log Pe correlation analysis.
Barbital is a known CNS(+) agent but is reported to penetrate slowly
across the membrane [59]. Indeed, its experimental log Pe value is more
like this for CNS(−) drugs. The CEC method gives a better prediction of
its CNS affinity. Determined log k parameter is high, indicating the
compound's interaction with the liposomal layer. Hexobarbital displays
a different permeability profile, as it is characterized by higher lipid
solubility and penetrates the brain very quickly [59]. In the case of this
drug, log k and log Pe values correlate well. Another outlier, zolpidem,
also penetrates rapidly across the membrane [80] and, in turn, is better
assessed by the PAMPA-BBB assay. The last one of the excluded drugs,
fexofenadine, undergoes carrier-mediated influx and efflux transport, so
it is hard to asses drug's permeability, using both “passive methods”.
The PAMPA-BBB assay classifies fexofenadine as a CNS(+) compound,
while the determined log k value indicates its low affinity to the bio-
logical membrane and in fact, the drug's CNS penetration is very lim-
ited. The results obtained for the excluded drugs well demonstrate the
limitations of in vitro techniques for BBB penetration estimation.
As the calculated correlation coefficients for the presented linear
regressions of log k and log BB/log Pe parameters are based on ex-
perimental data of a small set of 25 drugs, it is hard and too early to
indicate clear ranges of log k values for CNS(+) and CNS(−) drugs,
similar to those for log Pe in the PAMPA-BBB assay. Nevertheless, even
at the early stage of method development, CEC proved to have the
potential to be a quick and useful tool for permeability prediction of
compounds. References with log k < −1.84 or log k > −1.61
(analysis under 20 kV voltage, with POPC/PS coating) are pre-
dominantly correctly assessed as CNS(−) or CNS(+) agents, respec-
tively (Table 2). From a qualitative point of view, the percentage of
correct predictions is comparable to the PAMPA-BBB assay data, as well
as to some other in vitro separation methods proposed for BBB perme-
ability assessment [11,12,17].
7. Conclusions
25 marketed drugs were used as references for the new, perme-
ability prediction CEC method development. The best parameters for
separation of reference compounds were obtained in the capillary of
50 μm internal diameter, coated with a POPC/PS liposome (80:20 mol
%) layer, under the applied voltage of 20 kV. Based on drug migration
times in the capillary, their log k parameters were calculated and then
correlated with experimental log BB and log Pe values. The final log k
Fig. 7. Correlation coefficient analysis with four references excluded from linear regression presented in Fig. 4A, due to other than passive diffusion processes,
affecting their log BB values. Cetirizine (marked in blue) is an outlier in the presented analysis. Caffeine and levodopa (both marked in violet), along with barbital
(marked in green) diminish the significance of the correlation; capillary with 50 μm of internal diameter, POPC/PS (80:20 mol%) liposome coating. (For inter-
pretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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and log BB linear regression was based on 21 reference data with
R2 = 0.4258, for 20 kV voltage. The obtained R2 value was better than
that calculated from the corresponding reference correlation of PAMPA-
BBB log Pe parameters and log BB in vivo data (R2 = 0.3678, n = 21).
The received correlation coefficients indicate obvious limitations of
non-cell based in vitro methods. Due to their simplifications, no such
technique will ever correlate very well with in vivo conditions.
Nevertheless, for screening purposes, the presented CEC tool is com-
parable to the PAMPA-BBB method widely used in early drug discovery.
For most references, CNS(+)/CNS(−) preliminary predictions are si-
milar in the case of both methods and also in agreement with drugs’
permeability literature classification. The presented model may be
further validated with the extent number of compounds, including
molecules predominantly charged in pH 7.4.
To conclude, the new method proves to have the potential to work
well as a simple tool for early BBB permeability assessment of research
compounds. It is an innovative, fast and relatively cheap alternative to
the PAMPA-BBB technique. Also, it utilizes a liposomal coating of bi-
layer structure, closely mimicking natural phospholipid bilayers of BBB.
Moreover, it preserves the main advantages of the other electrophoretic
strategies, as well as the chromatographic separation models based on
LC. In our opinion, it is worth following up on this method based on its
potential application at the early drug discovery stage.
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